Wenge Xing

Wenge Xing


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2012 in Virology Journal
Verified
Journal Article
Open access
PDF file
HDHuahuang Dong
Huahuang Dong
JLJianli Liu
Jianli Liu
HZHong Zhu
Hong Zhu
COChin-Yih Ou
Chin-Yih Ou
WXWenge Xing
Wenge Xing
YJYan Jiang
Yan Jiang
Background: HIV-1 p24 antigen is a major viral component of human immunodeficiency virus type 1 (HIV-1) which can be used to identify persons in the early stage of infection and transmission of HIV-1 from infected mothers to infants. The detection of p24 is usually accomplished by using an enzyme-linked immunosorbent assay (ELISA) with low detection sensitivity. Here we report the use of two bio-barcode amplification (BCA) assays combined with polymerase chain reaction (PCR) and gel electrophoresis to quantify HIV-1 p24 antigen. Method: A pair of anti-p24 monoclonal antibodies (mAbs) were used in BCA assays to capture HIV-1 p24 antigen in a sandwich format and allowed for the quantitative measurement of captured p24 using PCR and gel electrophoresis. The first 1 G12 mAb was coated on microplate wells or magnetic microparticles (MMPs) to capture free p24 antigens. Captured p24 in turn captured 1D4 mAb coated gold nanoparticle probes (GNPs) containing double-stranded DNA oligonucleotides. One strand of the oligonucleotides was covalently immobilized whereas the unbound complimentary bio-barcode DNA strand could be released upon heating. The released bio-barcode DNA was amplified by PCR, electrophoresed in agarose gel and quantified. Results: The in-house ELISA assay was found to quantify p24 antigen with a limit of detection (LOD) of 1,000 pg/ml and a linear range between 3,000 and 100,000 pg/ml. In contrast, the BCA-based microplate method yielded an LOD of 1 pg/ml and a linear detection range from 1 to 10,000 pg/ml. The BCA-based MMP method yielded an LOD of 0.1 pg/ml and a linear detection range from 0.1 to 1,000 pg/ml. Conclusions: When combined with PCR and simple gel electrophoresis, BCA-based microplate and MMPs assays can be used to quantify HIV-1 p24 antigen. These methods are 3–4 orders of magnitude more sensitive than our in-house ELISA-based assay and may provide a useful approach to detect p24 in patients newly infected with HIV.

9 January 2021 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
BCBing Chen
Bing Chen
ZMZhong‐Hui Ma
Zhong‐Hui Ma
BXBing Xu
Bing Xu
HCHao Chang
Hao Chang
XHXiao‐Xia He
Xiao‐Xia He
WXWenge Xing
Wenge Xing

18 October 2022 in VirusDisease
Verified
Journal Article
Closed access
PDF file
BCBing Chen
Bing Chen
LGLing-Yu Gao
Ling-Yu Gao
ZMZhong-Hui Ma
Zhong-Hui Ma
HCHao Chang
Hao Chang
LPLi-Jian Pei
Li-Jian Pei
WXWenge Xing
Wenge Xing

20 May 2021 in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Verified
Journal Article
Closed access
BXB Xu
B Xu
BCB Chen
B Chen
ZMZ H Ma
Z H Ma
YRY N Ren
Y N Ren
JMJ Q Ma
J Q Ma
WXWenge Xing
Wenge Xing
Objective: To explore the diagnostic value of anti-HCV and HCV RNA so as to provide an accurate and efficient detection strategy for the diagnosis of HCV in intravenous drug users. Methods: 527 plasma samples from intravenous drug users were collected, and preliminary anti-HCV ELISA screening test was performed. A recombinant immunoblot assay (RIBA) was used as confirmatory assay for reactive antibody samples. All samples were tested for HCV RNA, followed by analysis of anti-HCV screening test, RIBA and HCV nucleic acid test results. Results: Anti-HCV ELISA results were reactive in 386 out of 527 intravenous drug users and non-reactive in 141. Among the 386 reactive antibody samples detected by RIBA, 370 cases were anti-HCV positive, 6 cases were anti-HCV indeterminate and 10 cases were anti-HCV negative. Anti-HCV ELISA and RIBA positive coincidence detection rate was 95.85% (370/386), and 70.21% (370/527) among intravenous drug users. HCV RNA was negative in all 10 anti-HCV RIBA non-reactive samples. 376 anti-HCV RIBA-positive and indeterminate samples were tested for HCV RNA, of which 56.93% (300/527) were current HCV infection, and 14.42% (76/527) were past HCV infection. Among 141 anti-HCV ELISA negative samples, the residual risk by anti-HCV ELISA screening for HCV RNA was 1.52% (8/527). HCV viral load distribution among intravenous drug users showed that the high viral load value (>10(7) IU/ml) and low viral load values (< 10(2) IU/ml) accounted for 1.95% and 2.27%, respectively, while the samples with viral load value of 1×10(2) ~ 1×10(7) IU/ mL accounted for 95.78% (295/308), and were mainly distributed in 1×10(5) ~ 1×10(6) IU/ml (37.99%). ELISA + RIBA + NAT assay detection strategies had differentiated 300 cases of current HCV infection, 76 cases of past HCV infection and 10 cases of false positive anti-HCV results, while ELISA+NAT assay detection strategies had only detected 300 cases of current HCV infection. However, of the 386 positive subjects screened for antibodies, 10 (2.59%) were undifferentiated false positives. Conclusion: Intravenous drug users are the high-risk population of HCV infection with high prevalence and high viral load. Anti-HCV screening for intravenous drug users will have a certain degree of residual risk. Therefore, anti-HCV ELISA screening and nucleic acid detection strategy can accurately diagnose the current infected patients; however, it cannot distinguish the false positive results of antibody screening.

20 February 2024
Verified
Journal Article
Closed access
LOL X Ou
L X Ou
WGW H Guo
W H Guo
YYY Yang
Y Yang
CZC L Zhu
C L Zhu
WXWenge Xing
Wenge Xing

2 June 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
HYHao Yan
Hao Yan
BXBing Xu
Bing Xu
QZQinyi Zhang
Qinyi Zhang
LZLijun Zhang
Lijun Zhang
ZFZhihan Fang
Zhihan Fang
WXWenge Xing
Wenge Xing
Introduction: Accurate, specific, and sensitive detection and quantification of hepatitis C virus (HCV) RNA are critical for diagnosing and managing HCV infections. This study evaluated and compared the performance of four commercially available HCV RNA quantification reagents using standardized serum panels, providing evidence-based insights for clinical applications.Methods: Performance metrics, including analytical sensitivity, specificity, limit of detection (LOD), precision, genotype inclusivity (GT 1–6), and linearity, were assessed using seven distinct serum panels: basic, analytical specificity, seroconversion, analytical sensitivity, precision, genotype qualification, and linearity panels.Results: All reagents demonstrated 100% analytical sensitivity and specificity (95% CI: 79.95–100), with no cross-reactivity to common interfering substances or viruses. LOD values for reagents A, B, C, and D were 25, 50, 50, and 50 IU/ml, respectively. Intra- and inter-assay coefficients of variation (CVs) for HCV genotypes 1–6 ranged from 1.48 to 4.37% and 1.74 to 4.84%, respectively. Strong linear correlations (R2 > 0.95) were observed between measured and expected HCV RNA levels across all reagents.Conclusion: These reagents exhibit high sensitivity, specificity, precision, and accuracy for HCV genotypes 1–6, with a wide linear range, making them suitable for clinical diagnosis and monitoring of HCV infections.